Skip Navigation

Chronic Somatic Syndromes Consortium

May 31, 2007

Morning Session

7:30 – 8:00


8:00 – 8:30

Welcome and introductions

8:30 – 10:00

Is there a consensus regarding the epidemiology, underlying mechanisms, and most effective treatments of these conditions?

D.J. Clauw UM

Before considering potential projects and deliverables of the consortium, we will first determine whether we can reach a consensus regarding these issues. Dr. Clauw will present a “straw-man” model for the group to comment upon.

10:00 – 10:15


10:15 – 12:30

How are these illnesses now viewed by different constituencies?

Even if thought leaders in these fields all agree on the above issues, these views might not be held by a variety of different constituencies that would need to be convinced of this new view. The speakers in this section will present the challenges and opportunities in these areas from each perspective.

10:15 – 10:45
How do sub-specialists view these illnesses?
E.A. Mayer UCLA
10:45 – 11:15
How do primary care physicians view these illnesses?
K. Kroenke IU
11:15 – 11:45
The CDC/NIH/government perspective
W.C. Reeves CDC,
Multiple NIH Researchers
11:45 – 12:30
The Industry Perspective. A representative from each of the pharma companies co-sponsoring the event will be asked to speak briefly regarding how they view this spectrum of illness, what types of consortium projects they may be willing to support, and what types of constraints they have regarding funding of such endeavors.

12:30 – 1:30


Afternoon Session

1:30 – 3:00

Working Groups

Consortium members and industry guests can self-select the working group meeting(s) they would like to attend. Each of these working groups will address the same set of questions:



Physician education programs / treatment guidelines T.L. Schwenk UM
Re-defining these illnesses (fibromyalgia clinical definition, primary care definition for chronic somatic syndrome) D.J. Clauw
Validating and using biomarkers for drug development E.A. Mayer UCLA
Using systems biology to better diagnose and treat this spectrum of illness W. Maixner UNC
Improved outcome measures D.A. Williams UM

3:00 – 5:00

Next Steps

Reports from each working group regarding recommendations for moving forward, followed by a plan for the future of the consortium.


Meeting adjourned